MRK Stock Recent News
MRK LATEST HEADLINES
Big pharma stocks, on balance, have been trading at a discount relative to the broader market for decades. Merck, a tier 1 U.S. pharmaceutical company, has been breaking out of this trend in 2024.
Moderna and Merck are collaborating on a personalized cancer vaccine. That vaccine program just disclosed some new data from the clinic.
In the closing of the recent trading day, Merck (MRK) stood at $126.15, denoting a -0.47% change from the preceding trading day.
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
Merck (MRK) concluded the recent trading session at $127.99, signifying a +0.26% move from its prior day's close.
Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.
Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
Here are 3 Dow Jones stocks to watch in the stock market today.
After a forgettable last year, Merck & Co., Inc.'s stock price is up 20% YTD, supported by approvals, a positive outlook for 2024, and an attractive forward P/E. Keytruda, the company's top-selling treatment, received approval from the European Commission, and hypertension treatment Winrevair received FDA approval. While its collaboration with Daiichi Sankyo and acquisitions reduced the EPS for 2023, Merck expects a turnaround this year, making for an attractive forward P/E compared to its 5y average.
Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs.